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Abstract The effect of activation of endogenous C-SW tyrosine 
kinase by (pY)EEI peptide was examined on voltage-operated 
calcium channel (VOC) currents in arterial smooth muscle cells. 
In single rabbit ear artery cells intracellular application of 
(pY)EEI peptide increased calcium channel currents. Inactive, 
non-phosphorylated YEEI peptide had no effect on currents. 
Peptide-A, a 21 amino acid inhibitor of c-Src inhibited currents 
and prevented the effect of (pY)EEI peptide on calcium channel 
currents. These results indicate that activation of intrinsic c-Src 
increases VOC and support a role for c-Src in the regulation of 
VOC in vascular smooth muscle cells. 
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1. Introduction 
Voltage-operated calcium channels (VOC) are a major 
route of calcium entry into the vascular smooth muscle cell 
[l]. Recently it has been proposed that tyrosine phosphoryla- 
tion by receptor and non-receptor tyrosine kinases may be an 
important mechanism by which VOCs are regulated in vascu- 
lar smooth muscle [2,3]. The product of the cellular src pro- 
tooncogene is a non-receptor tyrosine kinase of 60 kDa 
known as c-Src that is widely distributed in many cells includ- 
ing smooth muscle cells and is the cellular counterpart of the 
product of the Rous sarcoma virus oncogene (v-src) [4]. c-Src 
is found in association with the cytoskeleton [5] and concen- 
trated around cellular attachmefit sites to the extracellular 
matrix, such as focal adhesions [6]. We have shown previously 
that intracellular application of human c-Src increased VOC 
currents in rabbit ear artery cells [3] indicating that exogenous 
c-Src could modulate channel function. Peptide A, an inhibi- 
tor of c-Src, inhibited the effects of c-Src and also reduced 
VOC currents in the absence of exogenous c-Src [3] suggesting 
that endogenous c-Src may regulate the availability of VOC in 
these cells. The finding of high levels of c-Src in smooth mus- 
cle [7] is consistent with this proposal. 
The activity of cellular c-Src is regulated by a variety of 
stimuli through tyrosine phosphorylation and dephosphoryla- 
tion reactions of c-Src itself. An important tyrosine residue 
found in the kinase domain of the c-Src molecule is Tyr416, the 
phosphorylation of which is essential for activation of c-Src 
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[8]. A conserved carboxyl-terminal tyrosine residue, Tyr5”, is 
also important for regulation, phosphorylation of which re- 
sults in inhibition of c-Src enzyme activity [9,10]. Such phos- 
phorylation-dependent inhibition appears to be a general fea- 
ture of members of the Src family tyrosine kinases such as Lck 
and Fyn [11,12], and is catalysed by another tyrosine kinase 
known as C-terminal Src kinase (CSK), which is not known 
to catalyse other tyrosine phosphorylation reactions [ 131. Also 
essential for this negative regulatory mechanism is the non- 
catalytic N-terminal Src homology 2 (SH2) domain of the c- 
Src molecule [14] and also the SH3 domain [15]. The inhibi- 
tion is due to an intramolecular reaction in which the Tyr527- 
phosphorylated tail of c-Src associates with the SH2 domain 
of the same c-Src molecule in a ‘closed’ (inactive) conforma- 
tion [16], inhibiting the catalytic domain and preventing inter- 
actions with other proteins [17]. However, this intramolecular 
association is a relatively weak interaction with only moderate 
affinity and specificity [18]. Therefore it is predicted that a 
protein with greater affinity to the Src SH2 domain than the 
c-Src tail, such as an activated growth factor receptor, would 
repel the c-Src tail from the SH2 domain and cause activation 
of c-Src [16]. 
c-Src SH2 domain is composed of approximately 100 amino 
acids and has the ability to bind specifically and with high 
affinity to tyrosine phosphorylated proteins [19]. The amino 
acid sequence pTyr-Glu-Glu-Ile ((pY)EEI) is known to bind 
with optimal affinity to Src SH2 domain [20]. A peptide con- 
taining this sequence has been shown to increase c-Src activity 
severalfold in vitro probably by competing with the c-Src tail 
[18] and represents a means of activating endogenous cellular 
c-Src. 
Therefore the objective of the present study was to further 
investigate the role of endogenous c-Src in regulating VOC in 
arterial smooth muscle cells using the c-Src activating peptide 
(pY)EEI. 
2. Materials and methods 
Single smooth muscle cells were freshly dispersed from rabbit ear 
arteries by an enzymatic method [21]. Short (2-3 mm) segments of 
artery were incubated for 50 min in a modified physiological salt 
solution (PSS) containing (mM): NaCl 130, KC1 6, CaClz 0.01, 
MgClz 1.2, glucose 14, and HEPES 10.7 buffered to pH 7.2 with 
NaOH, 2 mg/ml bovine serum albumin, 1 mg/ml collagenase (130 U 
mg-‘), 0.5 mg/ml papain (15 U mg-‘) and 5 mM dithiothreitol. Cells 
were dispersed by mild agitation and resuspended after centrifugation 
in normal PSS containing 1.7 mM CaClz. Cells were stored on cover 
slips at 4°C and used within 46 h. Internal pipette solution contained 
(mMj: NaCl 126. M&IV 1.2. EGTA 2. MtiTP 2. TEA 10. and 
HEPkS 11 bufferdd to pfi 7.2’ with NaOH. Fatch pipettes were fab- 
ricated from borosilicate glass and had a resistance of 3-5 MR. 
Calcium channel currents were measured by the whole cell config- 
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uration of the patch clamp technique [22] using a List EPC-7 amplifier 
and a Labmaster AZD interface board with commercially available 
software (Pclamp 5.5, Axon Instruments, CA, USA) on a IBM-com- 
patible PC. The experiments were carried out in a ‘high barium’ solu- 
tion (BaCls 110 mM, HEPES 10 mM and buffered to pH 7.2 with 
TEA-OH) to increase the size of the inward current and to minimise 
calcium-dependent inactivation of currents [23]. Data were recorded 
on-line, or on digital audio tape using a DAT recorder (Biologic, 
France), and analysed off-line after analogue-to-digital conversion. 
The currents were digitally filtered at 2 kHz and leak currents were 
subtracted digitally, using average values of steady leakage currents 
elicited by a 10 mV hyperpolarising pulse [23]. All recordings were 
made at room temperature (22-25°C). 
1 mM stock solutions of (pY)EEI (active) and YEEI (inactive) 
peptides were made up in distilled water. Stock solution of peptide 
A (400 pM) was made up in ethanol. The final concentration of 
ethanol used (1%) has been previously shown to have no effect on 
VOC [3]. All peptides were included in the intracellular pipette solu- 
tion. A final concentration in excess of the reported ECss values were 
used for peptide A and (pY)EEI peptides. To minimise batch to batch 
variations, the effects of (pY)EEI, YEEI and peptide A were com- 
pared in cells obtained from the same isolates. 
2.1. Data analysis 
To investigate the effect of (pY)EEI on the voltage dependence of 
activation and inactivation, activation and inactivation curves were 
calculated. The activation curve was derived from the current-voltage 
relationships, Conductance (g) was calculated from the equation: 
g= ZB,I(E,-E,,,), where Zna is the peak current elicited by depolaris- 
ing test pulses to various test potentials (Em). E,, is the reversal 
potential estimated from the current-voltage curves. The conductance 
data was fitted to a Boltzman function: g= ll[l+exp{(E,,,-I’#}], 
where vh is the potential required for half activation and k is the 
slope factor. 
The steady-state inactivation curve was obtained from a double- 
pulse protocol. The data were also fitted to a Boltzman equation: 
Z= [Z,,/l+exp{E,-Vh}/k]+Z,,,, where Z is the peak current at any 
potential, Z,, is the maximum peak current evoked by such a step, 
vh is the potential at which current is half inactivated, k is a slope 
factor and Z,,, is the non-inactivating fraction of current. Data were 
fitted by non-linear regression analysing using Microsoft Excel. 
Data are presented as means f S.E.M of (n) observations. Compar- 
isons of data were made using a Student’s t-test for single paired or 
unpaired comparisons as appropriate. P < 0.05 was considered statis- 
tically significant. 
2.2. Drugs and chemicals 
Bovine serum albumin (essentially fatty acid free) and papain (Sig- 
ma. Dorset. UK). collaeenase (Worthineton, Readine. UK). aentide 
A \vAPSDSIQ~;EE~~FGKITRRE) (Novabiochem; Not&&am, 
UK), (pY)EEI peptide (EPQY(POsHs)EEIPIYL) and YEEI (LC 
Laboratories, UK), all other chemicals from Sigma, Dorset, UK. 
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Fig. 1. Effect of activation of endogenous c-Src by (pY)EEI peptide 
on calcium channel currents. Peptides were contained in the intracel- 
lular pipette solution and calcium channel currents measured using 
whole cell voltage clamp techniques in a single ear artery cell with 
110 mM Ba2+ as the charge carrier. Currents were evoked every 1 s 
following achieving whole cell mode using a 20 ms depolarising step 
to +lO mV from a holding potential of -60 mV. The figure shows 
calcium channel currents recorded from individual cells following es- 
tablishment of whole cell mode. (0) (pY)EEI peptide 100 pM; (A) 
YEEI peptide 100 PM; (0) (pY)EEI 100 pM in the presence of pep- 
tide A (100 PM). Results are representative of 5-8 similar experi- 
ments. 
peptide (non-phosphorylated) did not have any significant ef- 
fect on the VOC currents when included in the pipette solu- 
tion (n = 5, Figs. 1 and 4). 
(pY)EEI peptide had no significant effect on the voltage 
dependence of the activation curve (Fig. 2). vh was shifted 
negligibly from 7.6 f 2 mV (control) to 9.6 f 3 mV ((pY)EEI) 
(n=4, P=O.4). Slope= -11.3 + 1 (control) and -8.1 + 1 
((pY)EEI). Similarly (pY)EEI did not affect the voltage de- 
pendence of the inactivation curve significantly (Fig. 3); vh 
was - 18.2 f 2 mV in control and - 16.1 + 6 mV following 
(pY)EEI (n = 4, P= 0.3) and slope = -13.7 f 3 (control) and 
-10.7 f 1 ((pY)EEI). 
3. Results 
4. Discussion 
In cells voltage clamped at a holding potential of -60 mV, 
the inclusion of (pY)EEI peptide (100 PM) in the pipette 
solution progressively increased calcium channel currents 
evoked every 1 s by a 20 ms step to +lO mV, from 58 f 8 
pA to reach a steady level of 90 f 14 pA at around 2-3 min. 
This corresponds to a 55.1 k 14% increase in current (n=6, 
PS 0.007, Figs. 1 and 4). The increase in current was ob- 
served to begin within l-2 min following establishing whole 
cell mode with a pipette solution containing (pY)EEI (Fig. 1). 
When peptide A (100 PM) was included in the pipette solution 
together with (pY)EEI peptide, (pY)EEI failed to increase 
calcium currents and the current was reduced by 21 f 2% 
(n = 5, P= 0.05, Figs. 1 and 4). As we have previously 
reported, addition of peptide A alone also reduced currents 
(Fig. 4). The effects of (pY)EEI and peptide A together and 
peptide A alone did not differ significantly. Control YEEI 
Voltage-operated calcium channels are the major route of 
calcium entry into vascular smooth muscle cells and are in- 
volved in vascular contraction [l], cell migration and prolif- 
eration [24]. It is increasingly recognised that tyrosine phos- 
phorylation by protein tyrosine kinases is important in 
regulating VOC in different cell types [25-271, and in vascular 
smooth muscle cells activation of tyrosine kinases, by platelet- 
derived growth factor (PDGF) receptor [2] or c-Src [3], in- 
creases calcium channel currents. It has been previously pro- 
posed that an endogenous tyrosine kinase may also have a 
physiological role in maintaining VOC availability under rest- 
ing conditions since selective low molecular weight inhibitors 
of tyrosine kinases reduced VOC currents [25]. c-Src was con- 
sidered a likely candidate for this role since it is found in large 
amounts in smooth muscle cells [7] including rabbit ear artery 
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Fig. 2. The effect of (pY)EEI peptide on the activation of voltage- 
dependent calcium channels. a: The mean current-voltage (IV) rela- 
tionship of calcium channel currents. IV relationships were derived 
from a holding potential of -60 mV by depolarising to various test 
potentials as shown in the protocol (inset). IV data were measured 
at least 34 min after establishment of whole cell mode when the 
size of the calcium channel currents had stabilised. (0) Control 
cells, (0) cells with intracellularly applied (pY)EEI (100 FM). b: Ac- 
tivation curve for calcium channels showing normalised conductance 
as a function of test potential (E,). Conductance data were calcu- 
lated as described in Section 2. The average reversal potential for 
calcium channels was not changed in the absence (62 f2 mV) or 
presence (61 f 1 mV) of (pY)EEI. Data were fitted to a Boltzman 
function as described in Section 2. (0) Control cells, (0) cells with 
intracellularly applied (pY)EEI (100 uM). Data are means? S.E.M. 
of 4 observations. 
cells (unpublished data) and may be activated by cell-matrix 
interactions [28]. In the present study we have provided con- 
firmatory evidence supporting such a role for endogenous c- 
Src in regulating VOC in vascular smooth muscle cells. 
The activity of endogenous c-Src is regulated in part 
through an intramolecular interaction between the tyrosine 
phosphorylated tail and the SH2 domain of c-&c [16]. Pep- 
tides containing the sequence Glu-Glu-Ile (EEI) bind to the 
Src SH2 domain with about 40-fold greater affinity than the 
Tyr527-phosphorylated c-Src tail sequence [29] which is com- 
posed of the amino acids (pY)Gln-Pro-Gly ((pY)QPG). 
(pY)EEI peptide is an artificial amino acid sequence derived 
from the hamster polyoma virus middle T antigen [30], con- 
sisting of 11 amino acids. (pY)EEI has been shown to inhibit 
binding of the PDGF receptor to c-Src and the related tyro- 
sine kinase Fyn by competing with the activated (tyrosine 
phosphorylated) PDGF receptor for binding to the SH2 do- 
mains of these enzymes [31]. (pY)EEI has also been shown to 
increase the activity of c-Src in vitro in NIH3T3 cells several- 
fold [18]. In our study (pY)EEI peptide increased the ampli- 
tude of VOC currents presumably by activating c-Src or a 
related endogenous tyrosine kinase. Although the amplitude 
of current was increased the estimated activation or inactiva- 
tion curves for calcium channel currents were not affected by 
the application of (pY)EEI suggesting that c-Src may modu- 
late the open probability of calcium channels rather than their 
voltage dependence of activation or inactivation. Further sin- 
gle channel studies will be necessary to confirm this hypoth- 
esis. 
The negative regulatory mechanism induced by the intra- 
molecular reaction between the tyrosine-phosphorylated tail 
and SH2 domain of c-Src is strictly dependent on phosphor- 
ylation of c-Src Tyr527, as substitution of this residue by phe- 
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Fig. 3. The effect of (pY)EEI peptide on the steady-state inactiva- 
tion of calcium channel currents. Cells were held at various condi- 
tioning voltages for 6 s to achieve inactivation, then held for 10 ms 
at the holding potential of -60 mV before currents were evoked by 
a 20 ms depolarizing step to +20 mV as shown in the voltage pro- 
tocol (inset). Mean Zna (a), or Zn, normalized with respect to Zna 
evoked following a -80 mV conditioning potential (b), is plotted 
against the conditioning potential. Inactivation data were measured 
at least 5-6 min after establishment of whole cell mode when the 
magnitude of Ias had stabilized. (0) Control cells, (0) cells dialysed 
with (pY)EEI (100 uM). Data are means? S.E.M. of 4 observa- 
tions. 
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Fig. 4. Effects of (pY)EEI, YEEI peptides and peptide A on vol- 
tage-operated calcium channel currents and the effect of peptide A 
on the response to (pY)EEI peptide. Figure shows % increase in 
peak current induced by the peptides (calculated as % increase in 
current measured at 34 min following establishment of whole cell 
mode when currents had reached a steady level compared with cur- 
rents measured 10 s after establishment of whole cell mode). Col- 
umns represent meansf S.E.M. of (a) observations. Currents were 
evoked by a 20 ms depolarization to +lO mV from a holding poten- 
tial of -60 mV. Peptides were included in the pipette solution. The 
% increase in currents by peptides was analysed using a Student’s C- 
test for paired data rP< 0.05). The effects of peptide A alone (col- 
umn 4) and peptide A in the presence of (pY)EEI (column 3) were 
compared using an unpaired t-test and did not differ significantly. 
nylalanine or dephosphorylation of Tyr527 results in activation 
of c-Src kinase [32,33]. In vitro studies have shown that the 
dephosphorylated YEEI peptide was unable to increase c-Src 
activity [18]. Similarly in our study dephosphorylated YEEI 
peptide had no effect on calcium channel currents. 
Peptide A is a synthetic peptide containing 21 amino acids 
which corresponds to the non-catalytic domain (residues 131- 
157) of v-Src tyrosine kinase and is known to inhibit the 
activity of c-Src [34]. It has no inhibitory effects on serine 
or threonine kinases although it may also inhibit the epider- 
ma1 growth factor receptor tyrosine kinase [34]. Peptide A 
inhibited VOC currents when applied intracellularly and 
also inhibited the calcium channel activating effect of exogen- 
ous c&c [3]. Application of peptide A together with (pY)EEI 
abolished the effect of (pY)EEI peptide suggesting that 
(pY)EEI increases VOC currents by activating endogenous 
c-Src. 
In conclusion these results show that in rabbit ear artery 
cells activation of c-Src or a closely related tyrosine kinase 
increases, and that inhibition of this kinase reduces, voltage- 
operated calcium channel currents. In view of these findings 
we propose that a c-Src-like non-receptor tyrosine kinase 
plays an important role in regulating VOC in vascular smooth 
S. Wijetunge, A. D. HughesIFEBS Letters 399 (1996) 63-56 
muscle cells under resting as well as under growth factor-acti- 
vated conditions. 
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